EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Distinct proteomic CSF profiles in genetic frontotemporal lobar degeneration

Julie F H De Houwer, Elise G Dopper, Renee van Buuren, Marijke Stokkel, Liset de Boer, Tine Swartenbroekx, Pam A Boesjes, Ana Rajicic iD, Aitana Sogorb-Esteve, Arabella Bouzigues iD, Lucy L Russell, Phoebe H Foster und 34 weitere

Brain · 03.08.2026 · 149 (8) · 2816-2830

DOI: 10.1093/brain/awaf457 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brain, online erschienen am 04.12.2025. Verfasst von Julie F H De Houwer und 45 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology and Alzheimer Centre, Erasmus MC University Medical Centre, Rotterdam 3015 GD, The Netherlands. Hauptthemen laut MEDLINE: Frontotemporal Lobar Degeneration, Proteomics. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Swedish Research Council, UCLH Biomedical Research Centre, Bluefield Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Fluid biomarkers to diagnose frontotemporal lobar degeneration (FTLD) are currently lacking. In this study, we aimed to identify proteomic changes in CSF associated with FTLD pathogenesis, focusing on signatures unique to different genetic groups. Additionally, we sought proteins distinguishing FTLD-spectrum disorders from controls. To this end, we measured a comprehensive library of over 2900 proteins in CSF using proximity extension assay technology in two well-characterized FTLD cohorts. The discovery cohort, selected from the GENFI cohort, included 47 symptomatic pathogenic variant carriers (22 C9orf72, 14 GRN, 10 MAPT and 1 TARDBP), 124 presymptomatic pathogenic variant carriers (55 C9orf72, 44 GRN, 24 MAPT and 1 TARDBP) and 57 healthy non-carriers. The validation cohort comprised individuals clinically diagnosed with an FTLD-spectrum disorder (n = 132) and cognitively intact controls (n = 32). We assessed differentially abundant proteins using linear regression, adjusting for age and sex. Over-representation analysis was conducted for the three genetic groups using Gene Ontology Biological Processes as the ontology source. To develop diagnostic tools, we applied a LASSO regression, establishing two types of panels: one to distinguish individuals with an FTLD-spectrum disorder from controls (FTLD panel) and another to differentiate individuals with underlying TDP pathology from controls (TDP panel). We observed 23 dysregulated proteins in symptomatic carriers. Of these, four were also significantly dysregulated (NEFL, TPM3, MSLN and DNM3) in the validation cohort. When focusing on genetic subgroups, 63 upregulated proteins were observed in symptomatic MAPT carriers, with enriched biological pathways linked to immune function. In symptomatic C9orf72 carriers, four proteins—related to energy metabolism—were upregulated. When limiting symptomatic carriers to GRN, six proteins were dysregulated, with enriched pathways involved in neuronal development and projection. Notably, NEFL and TPM3 were consistently significant in all comparisons across both cohorts. We developed two diagnostic panels: one for FTLD and one for FTLD-TDP. The FTLD panel consisted of six proteins (NEFL, RBFOX3, NPTX1, TFF1, ENTPD5 and CNP). The TDP panel was made up of seven proteins (NEFL, RBFOX3, CBLN4, ENTPD5, CCL25, CNP and MMP1). Both panels were successfully replicated in the validation cohort (AUC of 0.94 and 0.96, respectively). This study highlights distinct proteomic signatures across FTLD genetic subgroups and their associated pathologies using a targeted proteomic approach. Additionally, we present two diagnostic panels—comprising both established and novel proteins—that effectively differentiate individuals with FTLD-spectrum disorders from healthy controls, offering promising avenues for improved clinical diagnosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Frontotemporal Lobar DegenerationProteomicsHumansFemaleMaleMiddle AgedAgedProgranulinstau ProteinsBiomarkersCohort StudiesC9orf72 Protein

Stichwörter der Autor:innen

dementiafamilialfrontotemporal dementiaolinkproteomeproximity extension-based assay

Substanzen

Progranulinstau ProteinsBiomarkersC9orf72 ProteinC9orf72 protein, humanMAPT protein, humanGRN protein, human

Autor:innen und Institutionen

  • Department of Neurology and Alzheimer Centre, Erasmus MC University Medical Centre, Rotterdam 3015 GD, The Netherlands.
  • Neurodegeneration, Amsterdam Neuroscience, Amsterdam 1081 HV, The Netherlands.
  • Neurochemistry Laboratory, Department of Laboratory Medicine, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam 1081 HV, The Netherlands.
  • Alzheimer Center Amsterdam, Neurology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam 1081 HV, The Netherlands.
  • Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London WC1N 3AR, UK.
  • UK Dementia Research Institute at University College London, London WC1N 3BG, UK.

ORCID-Profile: Ana Rajicic, Arabella Bouzigues, Lize C Jiskoot, Raquel Sanchez-Valle, Caroline Graff, Rik Vandenberghe, Alexander Gerhard, Johannes Levin, Maxime Bertoux, Simon Ducharme, Chris R Butler, Elizabeth Finger, Matthis Synofzik, Barbara Borroni, Henrik Zetterberg, Betty M Tijms, Charlotte Teunissen, Harro Seelaar

Förderung

  • Swedish Research Council
  • UCLH Biomedical Research Centre
  • Bluefield Project
  • Ontario Brain Institute
  • Alzheimer Nederland
  • Italian Ministry of Health
  • Wellcome Trust
  • Horizon Europe

Zitieren

APA

De Houwer, J. F. H., Dopper, E. G., van Buuren, R., Stokkel, M., de Boer, L., Swartenbroekx, T., Boesjes, P. A., Rajicic, A., Sogorb-Esteve, A., Bouzigues, A., Russell, L. L., Foster, P. H., Ferry-Bolder, E., van Swieten, J. C., Jiskoot, L. C., Sanchez-Valle, R., Laforce, R., Graff, C., Galimberti, D., …, & GENFI Consortium Members (2026). Distinct proteomic CSF profiles in genetic frontotemporal lobar degeneration. Brain, 149(8), 2816-2830. https://doi.org/10.1093/brain/awaf457

Vancouver

De Houwer JFH, Dopper EG, van Buuren R, Stokkel M, de Boer L, Swartenbroekx T, et al. Distinct proteomic CSF profiles in genetic frontotemporal lobar degeneration. Brain. 2026;149(8):2816-2830. doi:10.1093/brain/awaf457

BibTeX
@article{DeHouwer2026,
  author = {De Houwer, Julie F H and Dopper, Elise G and van Buuren, Renee and Stokkel, Marijke and de Boer, Liset and Swartenbroekx, Tine and Boesjes, Pam A and Rajicic, Ana and Sogorb-Esteve, Aitana and Bouzigues, Arabella and Russell, Lucy L and Foster, Phoebe H and Ferry-Bolder, Eve and van Swieten, John C and Jiskoot, Lize C and Sanchez-Valle, Raquel and Laforce, Robert and Graff, Caroline and Galimberti, Daniela and Vandenberghe, Rik and de Mendonça, Alexandre and Tiraboschi, Pietro and Santana, Isabel and Gerhard, Alexander and Levin, Johannes and Nacmias, Benedetta and Otto, Markus and Bertoux, Maxime and Lebouvier, Thibaud and Ducharme, Simon and Butler, Chris R and Le Ber, Isabelle and Finger, Elizabeth and Tartaglia, Maria Carmela and Masellis, Mario and Rowe, James B and Synofzik, Matthis and Moreno, Fermin and Borroni, Barbara and Zetterberg, Henrik and Rohrer, Jonathan D and Tijms, Betty M and Pijnenburg, Yolande A L and Teunissen, Charlotte and Seelaar, Harro and GENFI Consortium Members, GENFI Consortium Members},
  title = {Distinct proteomic CSF profiles in genetic frontotemporal lobar degeneration},
  journal = {Brain},
  year = {2026},
  volume = {149},
  number = {8},
  pages = {2816--2830},
  doi = {10.1093/brain/awaf457}
}
Kostenlos starten →